Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Interested in the high growth prospects of the biotech industry? For a closer look at some interesting biotech stocks, we ran a screen.

We began by screening the biotech industry for stocks with strong liquidity, with current ratios above 3. The current ratio is current assets/current liabilities, so ratios above 3 indicate the company has at least 3 times the liquid assets to cover their short-term liabilities.

We then screened these names for those with the confidence of their company insiders, such as members of the board and upper management, with significant net insider purchases over the last six months representing at least 2% of share float. Since most companies only have a handful of company insiders, net insider purchases representing 2% of share float is a big show of confidence in their employer's prospects.

(click to enlarge)

Do you think these stocks are poised to move higher? Use this list as a starting point for your own analysis.

List sorted by net insider purchases over the last six months as a percent of share float.

1. Repros Therapeutics Inc. (RPRX): Market cap at $117.52M, most recent closing price at $7.93. Current ratio at 13.65. Over the last six months, insiders were net buyers of 750,000 shares, which represents about 8.31% of the company's 9.02M share float.

2. QLT Inc. (QLTI): Engages in the development and commercialization of therapies for the eye. Market cap at $344.96M, most recent closing price at $7.03. Current ratio at 18.91. Over the last six months, insiders were net buyers of 1,655,013 shares, which represents about 5.6% of the company's 29.55M share float.

3. ViroPharma Inc. (VPHM): Engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Market cap at $1.4B, most recent closing price at $20.07. Current ratio at 6.12. Over the last six months, insiders were net buyers of 2,020,227 shares, which represents about 3.22% of the company's 62.83M share float.

4. ZIOPHARM Oncology, Inc. (ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Market cap at $406.35M, most recent closing price at $5.11. Current ratio at 9.69. Over the last six months, insiders were net buyers of 1,351,460 shares, which represents about 2.5% of the company's 54.15M share float.

*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: 4 Highly Liquid Biotech Stocks Being Snapped Up By Insiders